Can M-30, M-65, and IL-6 serum levels be useful markers in the diagnosis of preeclampsia and gestational diabetes?

Basit Öğe Kaydı
dc.authoridJafarzade, Aytaj/0000-0002-2999-9992
dc.authorwosidJafarzade, Aytaj/GRS-8983-2022
dc.contributor.authorJafarzade, A.
dc.contributor.authorBulut, B.
dc.contributor.authorBulut, H.
dc.contributor.authorMihmanli, V.
dc.date.accessioned2024-05-19T14:39:07Z
dc.date.available2024-05-19T14:39:07Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstract- OBJECTIVE: We aimed to evaluate the maternal and fetal serum M-30, M-65 and IL -6 levels in preeclampsia and gestational diabetes mellitus (GDM) in both maternal and cord blood. PATIENTS AND METHODS: Women with pre-eclampsia (n=30), GDM (n=30), and uncomplicated pregnancy (n=28) were evaluated in a cross-sec-tional study. After clamping during delivery, the serum M-30, M-65, and IL-6 levels were measured in both maternal venous blood and cord blood.RESULTS: The serum M-30, M-65, and IL-6 levels were significantly higher in preeclampsia and GDM patients' maternal blood and cord blood samples compared to the control group. In the preeclampsia group, M-65 was significantly high-er in cord blood compared with the level in mater -nal serum, but there was no significant difference between the GDM and control groups. The con-trol group's IL-6 level in cord blood was statisti-cally significantly lower than the other groups. Al-though the M-30 value in both maternal and cord blood was statistically lower in the control group than in the GDM group, there was no significant difference between the two groups when com-pared to the preeclampsia group.CONCLUSIONS: M-30 and M-65 molecules appear to have the potential to serve as bio-chemical markers in placental diseases, partic-ularly preeclampsia and gestational diabetes. Due to the insufficient sample sizes, more re-search is needed.en_US
dc.identifier.endpage5802en_US
dc.identifier.issn1128-3602
dc.identifier.issue12en_US
dc.identifier.pmid37401316en_US
dc.identifier.startpage5795en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4704
dc.identifier.volume27en_US
dc.identifier.wosWOS:001036880000018en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectApoptosisen_US
dc.subjectNecrosisen_US
dc.subjectInflammationen_US
dc.subjectCytokeratin-18en_US
dc.subjectPreeclampsiaen_US
dc.subjectM-30en_US
dc.subjectM-65en_US
dc.subjectPreeclampsia Predictionen_US
dc.titleCan M-30, M-65, and IL-6 serum levels be useful markers in the diagnosis of preeclampsia and gestational diabetes?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu